Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.60 (
caspase-7
)
920
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Spinocerebellar ataxia type 7 (SCA7) is a polyglutamine (polyQ) disorder characterized by specific degeneration of cerebellar, brainstem, and retinal neurons. Although they share little sequence homology, proteins implicated in polyQ disorders have common properties beyond their characteristic polyQ tract. These include the production of proteolytic fragments, nuclear accumulation, and processing by caspases. Here we report that
ataxin-7
is cleaved by
caspase-7
, and we map two putative
caspase-7
cleavage sites to Asp residues at positions 266 and 344 of the
ataxin-7
protein. Site-directed mutagenesis of these two
caspase-7
cleavage sites in the polyQ-expanded form of
ataxin-7
produces an
ataxin-7
D266N/D344N protein that is resistant to caspase cleavage. Although
ataxin-7
displays toxicity, forms nuclear aggregates, and represses transcription in human embryonic kidney 293T cells in a polyQ length-dependent manner, expression of the non-cleavable D266N/D344N form of polyQ-expanded
ataxin-7
attenuated cell death, aggregate formation, and transcriptional interference. Expression of the
caspase-7
truncation product of
ataxin-7
-69Q or -92Q, which removes the putative nuclear export signal and nuclear localization signals of
ataxin-7
, showed increased cellular toxicity. We also detected N-terminal polyQ-expanded
ataxin-7
cleavage products in SCA7 transgenic mice similar in size to those generated by
caspase-7
cleavage. In a SCA7 transgenic mouse model, recruitment of
caspase-7
into the nucleus by polyQ-expanded
ataxin-7
correlated with its activation. Our results, thus, suggest that proteolytic processing of
ataxin-7
by
caspase-7
may contribute to SCA7 disease pathogenesis.
...
PMID:Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. 1764 70
Polyglutamine (polyQ) expansion within the
ataxin-7
protein, a member of the STAGA [SPT3-TAF(II)31-GCN5L acetylase] and TFTC (GCN5 and TRRAP) chromatin remodeling complexes, causes the neurodegenerative disease spinocerebellar ataxia type 7 (SCA7). Proteolytic processing of
ataxin-7
by
caspase-7
generates N-terminal toxic polyQ-containing fragments that accumulate with disease progression and play an important role in SCA7 pathogenesis. To elucidate the basis for the toxicity of these fragments, we evaluated which posttranslational modifications of the N-terminal fragment of
ataxin-7
modulate turnover and toxicity. Here, we show that mutating lysine 257 (K257), an amino acid adjacent to the
caspase-7
cleavage site of
ataxin-7
regulates turnover of the truncation product in a repeat-dependent manner. Modification of
ataxin-7
K257 by acetylation promotes accumulation of the fragment, while unmodified
ataxin-7
is degraded. The degradation of the
caspase-7
cleavage product is mediated by macroautophagy in cell culture and primary neuron models of SCA7. Consistent with this, the fragment colocalizes with autophagic vesicle markers, and enhanced fragment accumulation increases in these lysosomal structures. We suggest that the levels of fragment accumulation within the cell is a key event in SCA7 neurodegeneration, and enhancing clearance of polyQ-containing fragments may be an effective target to reduce neurotoxicity in SCA7.
...
PMID:Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment. 1995 65
Recent studies have highlighted the importance of the lysosome in degrading proteins that misfold in neurodegenerative diseases. In this study we explore the role for autophagy in the clearance of an N-terminal
caspase-7
-generated fragment of
ataxin-7
, a protein with a pathogenic polyglutamine (polyQ) expansion in the neurodegenerative disease spinocerebellar ataxia 7 (SCA7). Using both cellular and transgenic mouse models of SCA7 we show that the stability of wild-type
ataxin-7
is modified by macroautophagy, but not by proteasomal, inhibition, whereas both autophagy and proteasomal degradation have little effect on polyQ-expanded
ataxin-7
. We also create a post-translational modification-deficient
ataxin-7
mutant that has increased protein turnover of both wild-type and polyQ-expanded
ataxin-7
, mediated through the autophagy pathway. Histological analysis reveals that wild-type
ataxin-7
colocalizes with markers of chaperone-mediated autophagy (CMA) and macroautophagy, indicating that both of these mechanisms may play a role in the clearance of
ataxin-7
. Furthermore, there is an increase in LC3, a marker of autophagy initiation, in the cerebellum of SCA7 transgenic mice. Our findings indicate that the
ataxin-7
fragment may be cleared via autophagy and that this process is altered in SCA7. Identification of the different types of autophagy involved in
ataxin-7
turnover and the influence of post-translational modifications on these processes will be pursued in future studies.
...
PMID:Autophagy: polyQ toxic fragment turnover. 2010 18
The neurodegenerative disorder spinocerebellar ataxia type 7 (SCA7) is caused by a polyglutamine (polyQ) expansion in the
ataxin-7
protein, categorizing SCA7 as one member of a large class of heritable neurodegenerative proteinopathies. Cleavage of
ataxin-7
by the protease
caspase-7
has been demonstrated in vitro, and the accumulation of proteolytic cleavage products in SCA7 patients and mouse models has been identified as an early pathological change. However, it remains unknown whether a causal relationship exists between
ataxin-7
proteolysis and in vivo SCA7 disease progression. To determine whether caspase cleavage is a critical event in SCA7 disease pathogenesis, we generated transgenic mice expressing polyQ-expanded
ataxin-7
with a second-site mutation (D266N) to prevent
caspase-7
proteolysis. When we compared SCA7-D266N mice with SCA7 mice lacking the D266N mutation, we found that SCA7-D266N mice exhibited improved motor performance, reduced neurodegeneration and substantial lifespan extension. Our findings indicate that proteolysis at the D266
caspase-7
cleavage site is an important mediator of
ataxin-7
neurotoxicity, suggesting that inhibition of
caspase-7
cleavage of polyQ-
ataxin-7
may be a promising therapeutic strategy for this untreatable disorder.
...
PMID:Proteolytic cleavage of ataxin-7 promotes SCA7 retinal degeneration and neurological dysfunction. 2585 8